MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
64.81
+1.02
+1.60%
After Hours: 64.81 0 0.00% 17:25 03/13 EDT
OPEN
63.99
PREV CLOSE
63.79
HIGH
66.25
LOW
63.10
VOLUME
790.20K
TURNOVER
--
52 WEEK HIGH
66.66
52 WEEK LOW
15.32
MARKET CAP
1.86B
P/E (TTM)
-140.8607
1D
5D
1M
3M
1Y
5Y
1D
AnaptysBio Is Maintained at Outperform by Wedbush
Dow Jones · 2d ago
AnaptysBio Price Target Raised to $75.00/Share From $60.00 by Wedbush
Dow Jones · 2d ago
Wedbush Maintains Outperform on AnaptysBio, Raises Price Target to $75
Benzinga · 2d ago
AnaptysBio (ANAB) Gets a Buy from Wedbush
TipRanks · 2d ago
ANAPTYSBIO INC <ANAB.O>: WEDBUSH RAISES TARGET PRICE TO $75 FROM $60
Reuters · 2d ago
AnaptysBio Price Target Raised to $50.00/Share From $36.00 by Truist Securities
Dow Jones · 5d ago
AnaptysBio Is Maintained at Hold by Truist Securities
Dow Jones · 5d ago
Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $50
Benzinga · 5d ago
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.